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The kingdom of fungi comprises a number of 
species that are associated with a wide spectrum 
of diseases in humans and animals, ranging 
from allergy and autoimmunity to life-threat-
ening infections [1]. However, fungal infections, 
though disparate in nature, are relatively rare, so 
that few fungal species regularly cause disease 
in immunocompetent individuals. Other fungi 
are able to establish lifelong commensalism on 
human skin and body surfaces without necessar-
ily causing disease [1]. This indicates that fungi, 
capable of colonizing almost every niche within 
the human body, must possess particular adap-
tation mechanisms of co-existence [2,3], which 
deviate into overt disease under conditions of 
deregulated immune responses. In fact, most 
fungi causing disease in humans act as oppor-
tunistic pathogens in individuals with specific 
immune defects. Patients with phagocytic, 
 cellular, combined and other primary immuno-
deficiencies, such as severe combined immuno-
deficiency, chronic mucocutaneous candidiasis 
(CMC), autoimmune polyendocrinopathy, 
candidiasis, ectodermal dystrophy, hyper-IgE 
syndrome, myeloperoxidase deficiency, leuko-
cyte adhesion deficiency, DiGeorge syndrome, 
XL-EDA-ID (defects of NF-kB essential modi-
fier), Wiskott–Aldrich syndrome and com-
mon variable immunodeficiency [4,5], exhibit 
increased susceptibility to fungal infections. In 
addition, Candida species remain an important 
cause of hospital-acquired bloodstream infec-
tions, particularly in the setting of solid organ 
transplantation [6], whereas invasive aspergillosis 
(IA) is a leading cause of infection-related death 
in hematopoietic stem cell transplant (HSCT) 
recipients [7]. Clinically, severe fungal infections 
also occur in patients with immune reconstitu-
tion syndrome, an entity characterized by local 
and systemic reactions that have both beneficial 
and deleterious effects on infection [8]. These 
patients may experience intractable fungal infec-
tions despite the occurrence of pathogen-specific 
immunity.
Fungal diseases also include type I hyper-
sensitivity, the most prevalent disease caused 
by airborne fungi, and a large number of other 
illnesses, including allergic bronchopulmonary 
mycoses, allergic chronic sinusitis, hypersensi-
tivity pneumonitis and atopic eczema/derma-
titis syndrome (formerly atopic dermatitis) [9]. 
Sensitization to molds has also been reported 
in patients with asthma and allergic broncho-
pulmonary aspergillosis (ABPA) is frequent in 
patients with asthma and cystic fibrosis [10]. 
Interestingly, there is evidence that fungal 
sensitization also contributes to autoreactivity 
against self-antigens due to shared epitopes with 
homologous fungal allergens [11].
The complex relationships of fungi with the 
vertebrate immune system are partly due to 
some prominent features. Among these, besides 
the genomic microvariation [12] to adapt to 
environ mental abiotic stress conditions [2,3], the 
ability to reversibly switch forms in infection 
may have resulted in an expanded repertoire of 
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cross-regulatory and overlapping antifungal host responses at dif-
ferent body sites. Examples include the thermally dimorphic fungi 
(e.g., Histoplasma capsulatum and Paracoccidioides brasiliensis), which 
transform from saprophytic filamentous molds to unicellular yeasts 
in the host, the filamentous fungi (such as Aspergillus species) that, 
inhaled as unicellular conidia, may transform into a multicellular 
mycelium, and some species of Candida, capable of growing in 
different forms such as yeasts, blastospores, pseudohyphae and 
hyphae. Thus, in the context of the antagonistic relationships that 
characterize the host–fungus interactions, the strategies used by 
the host to limit fungal infectivity are necessarily disparate; in 
retaliation, fungi have developed their own elaborate tactics to 
evade or modulate host defenses and to survive [13,14]. However, 
because fungal diseases are rare, an unwavering host–fungus 
interface is a likely requisite for most, potentially pathogenic, 
fungi. This demands for a tight balance of pro- and anti-inflam-
matory signaling pathways at the host–fungus interface in order 
to achieve the two-component antifungal response that includes 
resistance, that is, the ability to limit fungal burden, and toler-
ance, for example, the ability to limit host damage caused by 
either the immune response or other mechanisms [13,15,16]. 
In this article, we describe the current understanding on the 
contribution of innate immune receptors, such as Toll-like recep-
tors (TLRs), to the achievement of the best-fitted host–fungus 
interaction. In addition, we will discuss the immune response to 
fungi as a genetically modulated event that may help to define 
the best individually tailored approaches to be integrated into 
new medical practices.
The immune response to fungal infections
Generation of a dominant Th1 response driven by IL-12 is 
essentially required for protective immunity against fungi (box 1). 
Through the production of the signature cytokine IFN-g and 
the help granted by opsonizing antibodies, Th1 cells are instru-
mental in the optimal activation of phagocytes at sites of infec-
tion. Therefore, the failure to deliver activating signals to effector 
phagocytes may predispose patients to overwhelming infections, 
limit the therapeutic efficacy of antifungals and antibodies, and 
favor persistency and/or commensalism [13]. Immunological 
studies in patients with polar forms of paracoccidioidomycosis 
demonstrated an association between Th1-biased reactivity and 
the asymptomatic and mild forms of the infection, as opposed to 
the positive correlation of Th2 responses with the severity of the 
disease and poor prognosis [17].
IL-4 acts as the most potent proximal signal for commitment to 
Th2 reactivity that dampens protective Th1 responses and favors 
fungal allergy. IL-4 may both deactivate and activate phagocytes 
and dendritic cells (DCs) for certain specialized functions; for 
instance, it may inhibit the antifungal effector activities of phago-
cytes, yet may promote IL-12 production by DCs [13]. However, 
susceptibility to fungal infections may not always be associated 
with an overt production of IL-4 [18]. Over the past several years, 
the demise of a Th1/Th2 dichotomy paradigm has been accom-
panied by a renaissance in probing the basic tenets of CD4+ 
T-cell biology. As a result, instead of only two distinct ‘fates’ for 
developing T cells, research has identified alternative fates and 
more flexibility in T-cell cytokine production than  previously 
envisioned [19].
Th17 cells are now known to be a separate lineage of effector 
Th cells contributing to immune pathogenesis previously attrib-
uted to the Th1 lineage [20]. They produce a unique cytokine 
signature (IL-17, IL-17F, IL-21 and IL-22) and express transcrip-
tion factors distinct from Th1 and Th2 cells. Naive mouse and 
human CD4+ T cells activated in the presence of TGF-b and IL-6 
express the transcription factor retinoid-related orphan receptor gt 
and become Th17 cells that are stabilized by DC-derived IL-23 
and amplified by IL-1 and IL-21. Several experimental studies 
and clinical investigations confirmed that IL-23-driven Th17 
cells, rather than the Th1 cell subset, mediate the inflammatory 
responses of autoimmune or infectious origin [21,22]. In addition, 
both IL-23 and the Th17 pathway correlate with disease severity 
and immunopathology in diverse infections [23–25], suggesting that 
IL-12 and IL-23 have distinct roles in promoting antimicrobial 
immune responses and disease in vivo.
Th17 cells have an important function in the host defense 
response against extracellular pathogens, but they also have 
become notorious for their role in the pathogenesis of many auto-
immune and allergic disorders. Emerging data on the mechanism 
by which Th17 cells induce tissue inflammation suggest that Th17 
cells first infiltrate the site of tissue inflammation and then recruit 
other proinflammatory effector T cells (including Th1 cells) and 
innate cells (including neutrophils) to sites of tissue inflammation. 
As IL-17 receptors are widely expressed on parenchymal/tissue 
cells and IL-17 induces production of IL-1, IL-6, tumor necrosis 
factor (TNF), matrix metalloproteinases, IL-8 and chemokines, 
these mediators coordinate infiltration of other cell types to the 
site of inflammation and mediate massive tissue inflammation at 
the site where IL-17 is abundantly produced.
Th17 cells are induced in fungal infections through TLR- and 
non-TLR-dependent signaling [25–33]. Th17 are present in the 
human T-cell memory repertoire to Candida albicans [34,35] and 
Aspergillus fumigatus [36,37], and defective Th17 cell differentiation 
has been linked to CMC in patients with primary immunodefi-
ciencies [38]. Although recent evidence support the importance of 
the Dectin-1/IL-17 axis in human mucocutaneous fungal infec-
tions [39], both positive and negative effects on immune resistance 
have been attributed to Th17 and IL-17 receptor (IL-17R) signal-
ing in experimental fungal infections [25,40,41]. Thus, the role of 
IL-17 and Th17 cells in immunity versus pathology in fungal 
infections and diseases remains controversial [42]. The high sus-
ceptibility to systemic [41] and oral [40] candidiasis in conditions 
of defective IL-17RA signaling has been taken to indicate the 
essential role of IL-17RA signaling in host defense to Candida 
through the ability of IL-17 to mobilize neutrophils and induce 
b-defensin-3. However, exogenous IL-17 administration failed 
to rescue the Th17 deficiency and actually caused severe adverse 
reactions [40]. IL-17A was dispensable for protection in gastric 
candidiasis, and in fact neutralization of IL-17A greatly reduced 
fungal burden and ameliorated the systemic and gastrointesti-
nal infections in IL-17RA-deficent mice. IL-17A was elevated 
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in IL-17F-deficient mice and contributed 
to susceptibility to the infection in these 
mice, suggesting that IL-17F, by inhibit-
ing IL-17A, may exert protective effects 
in candidiasis. However, the finding that 
IL-17A blockade increased resistance in 
IL-17F-deficient mice clearly indicated 
that neither cytokine is essential in infec-
tion [43]. It is likely that the protective versus 
disease-promoting effect of the IL-17/Th17 
pathway may depend on the stage and site 
of infection, with early IL-17 able to exert 
some forms of antifungal resistance via 
IL-22 [43], defensins and neutro phils. On 
the other hand, the failure to downregulate 
microbe-induced expression of IL-17 could eventually be one 
major link connecting infection with chronic inflammation.
The mechanisms that have linked inflammation to chronic 
infection have been the offending potential of IL-17A that 
impeded the timely restriction of neutrophil inflammatory poten-
tial, preventing optimal protection to occur [44]. IL-17A also acti-
vated the inflammatory program of neutrophils by counteract-
ing IFN-g-dependent activation of indoleamine-2,3-dioxygenase 
(IDO), known to limit the inflammatory status of neutrophils, as 
well as by inducing the release of metalloproteinases and oxidants, 
which likely accounts for the high inflammatory pathology and 
tissue destruction associated with Th17 cell activation. Evidence 
indicates that the detrimental side effect of the inflammatory 
action of an unopposed IL-23/IL-17 pathway, which is under 
physiological conditions restrained by IDO, occurs through a 
mechanism leading to the sequential generation of regulatory 
and anti-inflammatory Vg4+ gd and CD25+ ab T cells [15]. This 
suggests that the intersection of gd cells (present in all vertebrates) 
with tryptophan catabolism (conserved through the past 600 mil-
lion years of evolution) might represent a milestone in the evolu-
tion of the immune system, combining the innate and acquired 
immune systems in the proper control of infection [44].
These new findings provide a molecular connection between 
the failure to resolve inflammation and lack of antifungal immune 
resistance and point to strategies for immune therapy of fungal 
infections that attempt to limit inflammation to stimulate an 
effective immune response. More generally, the Th17 pathway 
could be involved in the immunopathogenesis of chronic fungal 
diseases where persistent fungal antigens may maintain immuno-
logical dysreactivity. In fact, IL-17 neutralization increased fungal 
clearance, ameliorated inflammatory pathology and restored pro-
tective Th1 antifungal resistance, a finding pointing to the thera-
peutic utility of immunomodulatory strategies aimed at reducing 
Th17-driven hyperinflammation in fungal infections [44].
Despite the excitement raised by the new findings, much 
remains to be learned, including the dependency of Th17 on the 
plasticity of human CD4+ T-cell differentiation and the relative 
contribution of the various populations of IL-17-producing cells to 
the pathogenesis of infections and diseases caused by the different 
fungi. In this regard, Th17 cells also produce IL-22, a member 
of the IL-10 family of cytokines, which has been shown to play a 
more important role than IL-17 in host defense in the lung and 
gut [45]. Recent findings suggest that the IL-23/IL-22/defensins 
pathway is crucially involved in the control of fungal growth at 
mucosal and nonmucosal sites, particularly in conditions of Th1 
deficiency [43]. Thus, further tweaking the Th17 model, Th17 
may exert its protective role in fungal infections through IL-22.
Fungal sensing by the innate immune system
The antigen-independent sensing of fungi by the innate immune 
system triggers a set of chronological events required for protec-
tion against the specific pathogen. Receptors on phagocytes not 
only mediate downstream intracellular events related to clear-
ance, but also participate in complex and disparate functions 
related to immunomodulation and activation of immunity, 
depending on the cell type. Therefore, in order to achieve opti-
mal activation of antigen-specific adaptive immunity, it is first 
necessary to activate the pathogen detection mechanisms of the 
innate immune system.
Toll-like receptors are pattern recognition receptors (PRRs) 
that participate in the mediation of microbial recognition and 
initiation of inflammatory and antimicrobial host defenses. 
TLRs are type I transmembrane proteins that share characteris-
tic extra cellular and cytoplasmic domains: a leucine-rich repeat 
extra cellular domain responsible for the recognition of invariant 
microbial structures, the so-called pathogen-associated molecu-
lar patterns (PAMPs) (Table 1), and a cytoplasmic tail contain-
ing a highly conserved region, known as the Toll/IL-1 receptor 
(TIR) domain, responsible for transducing intracellular signals 
[46]. Upon ligand binding, TLRs recruit TIR domain-containing 
adapter proteins to the cytoplasmic portion of the TLRs through 
homophilic interaction of their TIR domains, inducing the acti-
vation of kinase cascades, ultimately leading to the activation 
of transcription factors such as NF-kB and the interferon regu-
latory factor family, which successively induce gene expression 
and production of various chemokines, cytokines and molecules 
required for antigen presentation or costimulation. Examples 
of the adapter molecules include MyD88 and TRIF [46]. The 
differential responses mediated by distinct TLR ligands can be 
explained in part by the selective usage of these adapter molecules.
Box 1. Major features of adaptive immune responses to fungi.
• Generation of a dominant Th1 response driven by IL-12/IFN-g is required for protective 
immunity against fungi [55]
• The MyD88-dependent pathway is required for Th1-mediated resistance [56,93,100]
• Th2 reactivity dampens Th1 responses and favors fungal allergy [55]
• Controversial role of Th17/IL-17 in immunity versus pathology in fungal infections 
[25,40–41,43,37]
• The TRIF/indoleamine-2,3-dioxygenase pathway inhibits Th17-cell development [15,26,49]
• Innate/adaptive IL-22 defines a novel pathway of antifungal resistance at mucosal 
surfaces [43]
• Regulatory T cells are essential components of antifungal immunity [155–157]
• Regulatory T cells may exacerbate fungal infections via immunosuppression [143,158]
• Dependency of regulatory T-cell induction on selected Toll-like receptors [26,143]
Cracking the Toll-like receptor code in fungal infections
Expert Rev. Anti Infect. Ther. 8(10), (2010)1124
Review
TLRs are expressed in various cell types including, but not 
limited to, monocytes, macrophages, DCs and neutrophils, and 
can be predominantly present on the cell surface (TLR-1, -2, 
-4, -5 and -6) or retained intracellularly in endosomes (TLR-3, 
-7, -8 and -9). Recent evidence also suggests an important 
contribution of TLRs to antimicrobial defense and immuno-
surveillance at epithelial surfaces [47–49]. Epithelial cells (ECs), 
no longer considered innocent bystanders [47], are now recog-
nized as central participants in innate and adaptive immune 
responses as well as in mucosal inflammation and allergy [50]. 
Through the activation of TLRs by endogenous and exogenous 
ligands, ECs may play a central role in determining the bal-
ance between a state of ‘mucosal homeostasis’, as is required 
for optimal organ function, and ‘mucosal injury’, leading to 
mucosal inflammation and barrier breakdown [47]. In the case of 
fungi, respiratory ECs sense germinating conidia of A. fumigatus 
through MyD88-dependent and -independent pathways [51]. 
In this regard, we have recently found that ECs contribute to 
antifungal immunity by providing protective tolerance through 
a TLR-3/TRIF-dependent pathway converging on IDO, a key 
regulator of the Th1/Treg versus Th17 balance in aspergill-
osis [49]. Similarly, ECs actively contribute to host resistance 
to C. albicans via immunological crosstalk with TLRs and 
neutro phils [48,52]. In addition to TLRs, other PRRs, including 
Dectin-1, may orchestrate the overall antifungal response at 
epithelial surfaces (see later).
Interaction of fungi with TLRs is nevertheless a complex process 
as, first, TLRs may function as homodimers or heterodimers (most 
notably TLR-2/TLR-1 and TLR-2/TLR-6) and may collaborate 
with other non-TLR PRRs in recognizing fungal ligands or in 
triggering intracellular signaling pathways. Second, expression of 
fungal ligands is different at the surface of fungal cells depending 
on the morphotype, a phenomenon that influences the type of host 
immune response induced. Therefore, the different impact of TLRs 
on innate and adaptive immunity is consistent with the ability of 
each individual receptor to activate specialized antifungal effector 
functions on innate immune cells, such as the respiratory burst, 
degranulation, and production of chemokines and cytokines [53–55]. 
Although the signaling pathways elicited by TLRs are known to be 
essential in controlling fungal infection [56], recent studies have also 
highlighted the pivotal role of C-type lectin receptors (CLRs), most 
notably Dectin-1, as the prototype of the innate non-TLR signaling 
pathway for antifungal sensing [57]. Dectin-1 is a myeloid-expressed 
transmembrane receptor that specifically recognizes the cell wall 
carbohydrate b-(1,3)-glucan of many fungi [58–60]. The cytoplas-
mic tail of the receptor contains an immunoreceptor tyrosine-based 
activation-like motif related to those of adaptive antigen receptors, 
which can mediate myeloid cell activation, cytokine production 
and a variety of antifungal responses either through the spleen tyro-
sine kinase Syk/cytoplasmic caspase recruiting domain 9 (CARD9) 
[28,61] or Raf-1 [62] pathways. As for TLRs, avoiding recognition 
by Dectin-1 could be a counterstrategy of fungi for immune eva-
sion [63,64]. The finding that human Dectin-1 deficiency has been 
associated with mucosal, but not invasive, Candida infections [39,65] 
suggests that Dectin-1 function may also be crucial to EC-mediated 
protection in mucosal candidiasis. In this regard, Dectin-1 has 
been shown to have an inducible expression in ECs [66]. However, 
given the ability of Dectin-1 signaling to activate canonical and 
noncanonical NF-kB pathways [62], known to have distinct, yet 
complementary roles in immunity and tolerance to fungi [67–69], 
this would predict additional and unexpected Dectin-1 functions in 
antifungal immunity and immunosurveillance at mucosal surfaces.
A number of fungal cell wall components may act through sev-
eral distinct PRRs, each activating specific antifungal programs 
on phagocytes and DCs [13,56,70,71] but cooperating for immune 
cell activation [54]. The environmental set-up also probably affects 
PRR function, given that the optimal ability of cells to phago-
cytose fungi is observed in the environment where a pathogen is 
naturally encountered [72]. However, another function of innate 
immunity that is emerging is its role in sterile inflammation – that 
is, inflammation caused by endogenous ligands. In this regard, 
implicated in fungal sensing are also nucleotide-binding domain 
leucine-rich repeat containing receptors (NLRs) that sense non-
microbial danger signals – that is, xenocompounds or molecules 
that when recognized alert the immune system of hazardous 
environments, perhaps independently of a microbial trigger – 
and form large cytoplasmic complexes called inflammasomes, 
most notably NLRP3, which link the sensing of fungal products 
and metabolic stress to the activation of inflammatory caspases, 
such as caspase-1, and the secretion of bioactive IL-1b and IL-18 
[73–75]. Consistently, Nlrp3-deficient mice are highly susceptible 
Table 1. Pattern recognition receptors sensing 
fungal-associated molecular patterns.
PRR PAMP Ref.
TLRs
TLR-2 Phospholipomannan
GXM
[84]
[92]
TLR-4 Mannan
O-linked mannosil residues
GXM
[96]
[97]
[92]
TLR-9 CpG oligodeoxynucleotides [111–113]
CLRs
MR Mannan
N-linked mannosil residues
[159]
[97]
Dectin-1 b-(1,3)-glucan [57,120]
Dectin-2 High mannose structures (Man
(9)
GlcNAc
(2)
) [160]
DC-SIGN Mannose structures [161]
Galectin-3 b-(1,2)-mannosides [129]
NLRs
NLRP3 Unknown [61,73]
CLR: C-type lectin receptor; DC-SIGN: Dendritic cell-specific intracellular 
adhesion molecule grabbing non-integrin; GXM: Glucuronoxylomannan;  
MR: Mannose receptor; NLR: Nucleotide-binding domain leucine-rich repeat 
containing receptor; PAMP: Pathogen-associated molecular pattern; 
PRR: Pattern recognition receptor; TLR: Toll-like receptor.
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to systemic [75–77] and mucosal [76] candi-
diasis, and a genetic polymorphism in the 
human gene encoding for NLRP3 was cor-
related with impaired IL-1b production 
upon C. albicans stimulation of peripheral 
blood mononuclear cells and with increased 
frequency of recurrent vulvovaginal candi-
diasis in women with vulvar vestibulitis 
syndrome [78]. Although the precise mech-
anisms of NLRP3 activation by fungi are 
still far from being completely understood, 
it is known that cell priming is required, 
for example, through PRRs such as TLRs 
and CLRs, to initiate NF-kB-dependent 
transcriptional upregulation of NLRP3 [79]. 
Altogether, the current knowledge in the 
field highlights how TLR activation itself is 
a ‘double-edged sword’, as members of the 
TLR family are involved in the pathogen-
esis of autoimmune, chronic inflammatory 
disorders such as asthma, rheumatoid arthritis and infectious 
diseases. Thus, by hyperinducing pro inflammatory cytokines, by 
facilitating tissue damage or by impairing protective immunity, 
TLRs might paradoxically promote the pathogenesis of infec-
tions [80]. Not surprisingly therefore, fungal pathogens are able to 
exploit PRR-based strategies to divert and subvert host immune 
responses to fungi [81].
TLRs in fungal infections
The initial observation that Toll-deficient Drosophila were unable 
to mount effective antifungal responses and were highly suscep-
tible to A. fumigatus infection [82] led to the assumption that mam-
malian TLRs also participated in antifungal immunity. In fact, 
TLR-2, -4 and -9 signaling has been particularly demonstrated to 
contribute to host responses against fungi both in mice (reviewed 
in [71]) and in humans (box 2) [83].
TLR-2
TLR-2 has been reported to recognize the phospholipomannan 
component of the Candida cell wall [84]. Although the first studies 
investigating TLR-2 function in antifungal host defense reported 
protection-associated consequences for TLR-2 signaling during 
infection [85,86], we found instead that TLR-2-deficient mice were 
more resistant to disseminated candidiasis, accompanied by a 
decreased production of IL-10, and increased IL-12 and INF-g 
production [56]. In line with our findings, TLR-2-deficient macro-
phages have been shown to have an enhanced capacity to contain 
C. albicans [87]. Moreover, a previously unanticipated role for TLR-2 
in the replenishment of the innate immune system during infec-
tion, integrating signals from extrinsic pathogens with those from 
normal growth and differentiation factors, rather than a direct 
effect on the antifungal immune capacity, has been demonstrated 
in a recent study in which TLR-2/MyD88-mediated recognition 
of C. albicans by hematopoietic stem and progenitor cells induced 
differentiation into functional phagocytes, required for the rapid 
generation of innate immune cells in response to the fungus [88]. 
In addition, a restricted role for TLR-1, and especially TLR-6, 
known to form heterodimers with TLR-2, has been reported in 
C. albicans recognition, although animals genetically deficient in 
these  receptors were not more susceptible to infection [89].
The consequences of the absence of TLR-2 in aspergillosis are 
more complex. Wang et al. reported no role for TLR-2 in the 
recognition of Aspergillus hyphae [90] and we also found that cyclo-
phosphamide-treated TLR-2-deficient mice did not present an 
increased susceptibility to aspergillosis, although fungal burden 
in the lungs was increased [56]. This was associated with higher 
numbers of lung IL-4-producing CD4+ T cells but also with 
higher TNF levels [56]. These findings are nevertheless in con-
trast with those using a model of IA in mice immuno suppressed 
with vinblastine, in which TLR-2-deficient animals had higher 
mortality rates and significantly lower levels of lung TNF than 
wild-type mice [91].
The role of TLR-2 in the recognition of Cryptococcus neoformans 
is also not clear, with studies reporting that TLR-2 can bind 
cryptococcal glucuronoxylomannan [92] and mediate cytokine 
production in response to the fungus [93], whereas other authors 
found that TLR-2 was not involved in cryptococcal-induced cyto-
kine production [94]. On the other hand, TLR-2 deficiency has 
recently been shown to promote chronic pulmonary infection by 
P. brasiliensis through the skewing towards a Th17 response asso-
ciated with diminished expansion of Treg cells and increased lung 
pathology due to unrestrained inflammation [95]. In conclusion, 
TLR-2 seems to play a role in fungal infection, although disagree-
ment persists regarding the precise components recognized and 
the amplitude of the effects.
TLR-4
TLR-4 is perhaps the most extensively studied PRR; it has been 
reported to recognize mannans from Saccharomyces cerevisiae 
and C. albicans [96], as well as short linear O-bound mannans 
Box 2. Major features of Toll-like receptors and Toll-like  
receptor-mediated signaling in fungal recognition.
• Distinct, yet controversial, roles of TLR-2 and TLR-4 in fungal recognition and 
inflammation [56,70,85–87,90–91]
• Requirement of TLR-2/MyD88 signaling to induce differentiation of bone marrow stem 
and progenitor cells to functional phagocytes in response to Candida albicans [88]
• Cooperation between the MyD88 and TRIF pathways for immunity and tolerance to 
C. albicans [26]
• Contribution of the MyD88 pathway in recognition and resistance to 
Aspergillus fumigatus [103,106,107]
• Beneficial effect of TLR-9 stimulation on immune-mediated resistance to fungal 
pneumonia [114,162]
• Requirement for TLR-9 in the modulation of immune responses to fungi in allergy [115]
• Collaboration between TLRs and Dectin-1 for the enhancement of antifungal immune 
responses [123–127,129]
• Exploitation of TLR signaling by fungi as a mechanism to divert and subvert host 
immune responses [81,163]
• Involvement of selected TLRs in the therapeutic activity of antifungals [164,165]
TLR: Toll-like receptor.
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of C. albicans, able to induce proinflammatory cytokines [97]. 
The first experimental models reported that the absence of 
TLR-4-mediated signals resulted in increased susceptibility to 
disseminated candidiasis, together with decreased induction 
of chemokines and impaired neutrophil recruitment at the site 
of infection [85]. In line with these observations, we found that 
TLR-4-deficient mice mounted a defective Th1 protective immu-
nity to the fungus in the face of an efficient innate antifungal 
resistance [56] and, more recently, absence of functional TLR-4 has 
been demonstrated to impair macrophage responses after C. albi-
cans infection [98]. Furthermore, TLR-4 also seems to be impor-
tant for adaptive immune responses induced by C. albicans [56]; 
in fact, stimulation of DCs by C. albicans was shown to induce 
TLR-4-dependent cytokine production including IFN-g and 
IL-12, resulting in protective Th1-mediated cellular responses [99].
A globally important role for TLR-4 and -2 in host defense 
against disseminated candidiasis was also demonstrated in part 
by the increased susceptibility of MyD88-deficient mice to 
C. albicans infection [56,100]. This adapter protein was shown to 
be involved in the induction of protective immune responses by 
DCs [56], as well as in phagocytosis, killing and cytokine produc-
tion by Candida-infected cells [56,101]. In addition, we found that 
generation of protective immunity to C. albicans relies on the pres-
ence of functionally and phenotypically distinct Treg cell subsets 
that are sequentially induced in the course of infection through a 
process implicating distinct, nonredundant roles of MyD88 and 
TRIF pathways. Sensing of the fungus through both MyD88 and 
TRIF pathways mediates the induction of a state of protective 
tolerance, in which fungal persistence is maintained in the context 
of a poorly inflammatory environment. IDO, known to have a 
central role in the induction of Th1 immunity within a regula-
tory environment [102], appears to be involved in TRIF-dependent 
tolerance to the fungus.
A role for TLR-4 in the recognition of A. fumigatus was sug-
gested for the first time by Wang et al. [90] and subsequent studies 
have shown that TLR-4 is involved in signaling and cytokine 
production in response to Aspergillus [103]. These findings were 
supported by our own data showing that TLR-4-deficient mice 
had significantly lower survival rates, higher lung fungal burdens 
and higher numbers of IL-4-producing CD4+ T cells [56], together 
with an inability to effectively clear the fungus [70]. Interestingly, 
otherwise immunocompetent mice genetically deficient in TLR-2, 
TLR-4, IL-1R1 or MyD88 are not susceptible to IA [56,104,105]. 
Despite these findings, TLR signaling through MyD88 appears to 
be necessary for the early inflammatory responses to Aspergillus in 
immunocompetent hosts, since in the absence of MyD88, fewer 
natural killer cells and higher fungal burdens in the infected lung 
were observed early after the fungal challenge [106]. Furthermore, 
MyD88-mediated signaling was required for the subsequent acti-
vation of protective adaptive responses [56,107]. In this regard, it 
is also noteworthy that the absence of a negative regulator of 
TLR signaling, Toll IL-1R8 (TIR8), in immunocompetent mice 
challenged with Aspergillus was found to reduce survival rates and 
increase lung fungal growth that were associated with elevated 
lung IL-17 and IFN-g levels but lower IL-10 and Foxp3 transcript 
levels, suggesting that the absence of this regulatory process results 
in the detrimental activation of Th1 and Th17 immunity [104].
TLR-4 is also involved in susceptibility to Pneumocystis pneu-
monia, with severe impairment in cytokine production being 
displayed by alveolar macrophages derived from mice deficient in 
TLR-4 [108]. By contrast, the C. neoformans component glucurono-
xylomannan binds to TLR-4 and leads to translocation of NF-kB, 
but not to induction of cytokine production [92], and these find-
ings were supported by the fact that TLR-4 does not play a major 
role in cryptococcal host defense [109]. More recently, TLR-4 
signaling has been shown to promote severe paracoccidioido-
mycosis, an effect mediated by vigorous inflammatory reactions 
and impaired expansion of Treg cells [110].
Overall, TLR-4 appears to play a major role in controlling the 
balance between detrimental and protective immune responses 
to the fungus through its ability to both promote (via MyD88) 
and inhibit (via TRIF) Th17 development (Figure 1) [26]. This 
suggests that conditions of high-threat inflammation may rep-
resent a local environmental factor that predispose to Th17 acti-
vation in candidiasis or aspergillosis. IL-17-producing cells are 
induced by Candida or Aspergillus through innate signaling via 
Dectin-1/CARD9 [28] and TLR/MyD88 [25] and they are inhib-
ited by negative regulators of TLRs [104] and TRIF [26]. Activation 
of pathogenic Th17 cells accounts for susceptibility to candidiasis 
and aspergillosis under conditions of deficient p35 [25], TRIF [26], 
TIR8/SIGIRR [104] or functional NADPH oxidase expression [15]. 
In all of these settings, Th17 pathway expression – rather than 
an unrestrained Th1 response – correlates directly with defective 
pathogen clearance, and failure to resolve inflammation as well as 
initiate protective responses to Candida and Aspergillus.
TLR-9
Unmethylated CpG sequences are the natural ligands for TLR-9 
and several reports have now suggested that TLR-9 can recognize 
fungal DNA [111–113]. While no increased susceptibility of TLR-9-
deficient mice to disseminated candidiasis has been observed, 
these animals tended to have lower fungal burdens [56], as well 
as less IL-12 and more IL-10 and IL-4 than control mice [12]. It 
is unclear why this shift towards an anti-inflammatory cytokine 
profile, known to be deleterious for the anti-candidal host defense, 
did not result in a deleterious effect on the outcome of the infec-
tion. Interestingly, DNA from C. albicans was found to activate 
bone marrow-derived DCs (BM-DCs) through a TLR-9-mediated 
signaling pathway, nevertheless using a mechanism independent 
of the unmethylated CpG motif [111]. This suggests that multiple 
TLR-9–PAMP interactions may occur in C. albicans recognition 
in order to enable the immune system to respond to the fungus 
in a more sensitive and specific way [54]. There is no data on CpG 
DNA as an adjuvant in C. albicans vaccination models, although 
it has been shown to enhance Th1-induced protection against IA 
in mice vaccinated with recombinant Aspergillus proteins [114].
TLR-9 has been shown to initiate immune responses to 
Aspergillus through the recognition of fungal unmethylated CpG 
DNA in murine BM-DCs and human plasmacytoid DCs, resulting 
in the secretion of proinflammatory cytokines [113]. Surprisingly, 
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peritoneal neutrophils from TLR-9-deficient mice have a greater 
ability to kill Aspergillus conidia and hyphae [70], and TLR-9-
deficient mouse lung DCs produce less IL-12p70 and more IL-10 
in response to conidia [56]. However, the role of TLR-9 in the con-
text of in vivo defense against Aspergillus appears to be more com-
plex. In the setting of immunosuppression or antibody-mediated 
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DC DC
MyD88
MyD88
TRIF
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Y
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Figure 1. The activation of distinct signaling pathways downstream Toll-like receptors in murine dendritic cells translates 
the recognition of the fungus into protective Th1/Treg or inflammatory Th2/Th17 responses. Two alternative downstream 
signaling pathways are activated through TLR-4 in tolerogenic DCs: a MyD88-dependent pathway, which results in the activation of p38/
canonical NF-kB, production of IL-12 and development of protective Th1 responses; or a TRIF-dependent pathway, which results in the 
production of IL-10 that, together with the activation of p38/STAT3/noncanonical NF-kB, leads to the activation of IDO and production 
of IL-27 and IFN-b, promoting Treg differentiation. In inflammatory DCs, the MyD88-dependent signaling occurring through TLR-2 is 
transduced through ERK, JNK, PI3K/Akt/mTOR and canonical NF-kB, leading to the production of either IL-10 and IL-4 and consequent 
nonprotective Th2 responses, or IL-23 and Th17 responses.
DC: Dendritic cell; IDO: Indoleamine 2,3-dioxygenase; NF: Nuclear factor; TLR: Toll-like receptor.  
Data taken from [67,68].
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neutrophil depletion, TLR-9-deficient mice survive longer and 
have significantly lower fungal burdens following challenges with 
Aspergillus conidia [56,70,115], suggesting the involvement of TLR-9 
signaling in an immunoregulatory mechanism that ultimately ben-
efits the fungus and may be mediated by neutrophils. In the context 
of airway hypersensitivity to Aspergillus, however, the absence of 
TLR-9 led to lower levels of methacholine-induced airway hyper-
reactivity but promoted fungal growth in the lung associated with 
reduced lung Dectin-1 expression levels; this is remarkable since 
wild-type mice sensitized to Aspergillus do not develop invasive 
disease following the administration of even large inocula in the 
setting of neutrophil depletion [116]. It remains to be established 
whether this effect is due to a failure of TLR-9-deficient mice to 
develop acquired immunity to Aspergillus during the sensitization 
or whether this finding is due to the absence of a TLR-9-mediated 
recognition of Aspergillus during the secondary challenge.
DNA from C. neoformans was also found to activate TLR-9, 
which was able to trigger IL-12p40 and expression of CD40 upon 
stimulation in murine DCs [112]. In conclusion, most of the data 
available at this time suggests a role for TLR-9 in the recognition 
of fungal DNA, but the magnitude of this effect for the overall 
antifungal defense is likely to be overshadowed by redundant 
signals induced by other PRRs.
Collaborative crosstalk between TLRs & Dectin-1
The first in vivo evidence that Dectin-1 plays an important role 
in innate fungal host defense was reported by a study showing 
that blocking Dectin-1 leads to increased A. fumigatus fungal 
burden in the lung [117]. Dectin-1-deficient mice are also more 
susceptible to infection with C. albicans, resulting in lower sur-
vival and increased fungal burdens [118]. However, another study 
using a different strain of mice deficient in Dectin-1 could not 
confirm this, but found an increased susceptibility to Pneumocystis 
infection [59]. Although it has been suggested that Dectin-1 is not 
likely essential for the development of host protective responses to 
C. neoformans [119], fungal spores were nevertheless found to be 
phagocytosed by alveolar macrophages via interactions between 
fungal b-(1,3)-glucan and the host receptors Dectin-1 and CD11b 
[120]. Accordingly, Dectin-1 has been suggested to play a pivotal 
role in P. brasiliensis recognition, internalization and consequent 
activation of the immune response against the fungus [121].
It has been demonstrated that infection with C. albicans induces 
CARD9-dependent Th17 cells [28], and that cytokine production 
induced by C. albicans by both human mononuclear cells and 
murine macrophages is dependent on Dectin-1 [122]. Although 
Dectin-1 signaling alone is sufficient to induce responses upon 
fungal recognition, several studies have emphasized that it is also 
able to cooperate with TLRs leading to synergistic proinflamma-
tory responses. In fact, Dectin-1 has been shown to collaborate 
with TLR-2 to trigger proinflammatory responses to C. albicans 
and zymosan [123,124], and to amplify TLR-4-dependent path-
ways in a Syk-dependent manner [125]. In fact, evidence for an 
anti-inflammatory role of TLR-2 in antifungal host defense has 
been supported by a study reporting zymosan to induce DC 
tolerogenesis through a TLR-2- and Dectin-1-mediated pathway 
involving MAPK/ERK signaling [126]. Furthermore, Dectin-1 
and TLR-2 also collaborate for the phagocytosis of Aspergillus 
conidia [127], and A. fumigatus can activate transcription through 
a Dectin-1/Syk-dependent pathway [128]. Overall, these findings 
suggest an important role for Dectin-1 in antifungal immunity, 
either directly or through collaborative signaling with TLR-2 
and/or TLR-4.
In addition to Dectin-1, several interactions between TLRs 
and other PRRs are well documented. Galectin-3, a PRR which 
recognizes b-(1,2)-mannosides, has recently been shown to 
associate with TLR-2, and this leads to the ability to discrimi-
nate between the pathogenic C. albicans and the nonpathogenic 
S. cerevisiae [129]. In addition, the TLR-2 pathway itself is able to 
inhibit TLR-4-mediated production of IL-12 through stabiliza-
tion of the c-Fos transcription factor [130]. Another study demon-
strated that when TLRs activate NF-kB, C. albicans can induce 
DC-SIGN-dependent signals, which subsequently lead to acety-
lation of the NF-kB subunit p65 [131]. This results in prolonged 
and increased IL-10 production that shifts the proinflammatory 
response induced by TLRs to a more anti-inflammatory profile 
[131]. All these observations imply that the crosstalk between PRRs 
is essential to the complexity and flexibility of the innate immune 
response against fungi.
Genetic variability of PRRs & human susceptibility to 
fungal infection
There is now undeniable evidence that genetic variants within 
recognition molecules involved in innate immunity may account, 
in part, for the inherited differences in human susceptibility to 
infection [132]. Given the broad effect of TLRs on immunity [46], 
their function in human disease, and specifically in fungal infec-
tions, has been investigated largely by comparing the incidence of 
disease among individuals with different polymorphisms in genes 
that participate in TLR signaling (Table 2). Accordingly, growing 
amounts of data suggest that the ability of certain individuals 
to properly respond to TLR ligands may be impaired by poly-
morphisms in TLR genes, resulting in an altered susceptibility to, 
or course of, infectious or inflammatory disease [133]. Most studies 
so far have focused on the highly polymorphic TLR-4 gene, in 
which two co-segregated missense polymorphisms – D299G and 
T399I – have been described to compromise the extra cellular 
ligand-binding domain of TLR-4 [134]. These variants have 
been linked with blunted airway [135] and systemic inflamma-
tory responses [136] to inhaled lipopolysaccharide in adults and 
attenuated lipopolysaccharide-induced responses in primary air-
way ECs [135]. Interestingly, the D299G substitution was found 
to have a greater functional impact compared with the T399I 
genotype [135]. Figure 2 illustrates the role of genetic polymorphisms 
in PRRs in susceptibility to fungal infections and their associated 
functional consequences on the host’s immune response to fungi.
The TLR-4 polymorphisms D299G and T399I have been 
shown to contribute to a higher risk of Candida bloodstream 
infection, supposedly through increased IL-10 production 
[137]. CMC patients were also reported to have increased IL-10 
over IFN-g production, possibly occurring in association with 
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D299G [138]. However, the extent to which these polymor-
phisms contribute to the hyperactivation immune status of 
CMC patients with autoimmune regulator gene mutations [139] 
is not known. IL-10 has been reported to inhibit the action 
of human monocytes against C. albicans [140], while in mice, 
the absence of IL-10 was associated with increased antifungal 
resistance [141]. However, in experimental candidiasis, IL-10 
exhibited both beneficial and detrimental effects depending on 
the degree of inflammation (reviewed in [16]). Therefore, despite 
the overall suppressive effect, IL-10 might be required to limit 
host damage under high levels of inflammation, a mechanism 
that may ultimately determine whether or not successful control 
of the infection will ensue. This may explain why the D299G 
polymorphism does not appear to play a role in susceptibility and 
severity of human urogenital C. albicans infection [142]. TLR-2-
dependent IL-10 production was also demonstrated in response 
to Candida and Aspergillus in experimental models of infection 
[56,143]. However, in candidiasis, the nonsynonymous R753Q 
polymorphism in human TLR-2 was shown to reduce IFN-g 
and IL-8 and increase TNF-a during Candida sepsis in intensive 
care unit patients [144]. The extent to which this deregulated 
cytokine production contributes to susceptibility to candidiasis 
is still not clear. Furthermore, no association between R753Q 
and susceptibility to IA, chronic cavitary pulmonary aspergillosis 
(CCPA) or ABPA was found [145–147].
One of the first studies investigating the functional conse-
quences of TLR-4 polymorphisms in aspergillosis described an 
increased frequency of CCPA among D299G carriers [146]. In 
CCPA patients, the fungus is able to grow in preformed lung 
cavities, therefore escaping immune surveillance. Considering 
that subjects harboring the D299G polymorphism have an 
additional defect in TLR-4 function, the increased susceptibil-
ity observed is likely due to an extensive impairment in fungal 
recognition. In the stem cell transplantation setting, the D299G 
polymorphism in TLR-4 was also found to increase susceptibility 
to IA in HSCT recipients from unrelated donors [148]. The fact 
that a previous study failed to associate the same donor TLR-4 
polymorphism with IA in HSCT patients [147], further stresses 
that the contribution of the D299G polymorphism may depend 
on the type of transplant and associated clinical variables. In 
this regard, we have recently described an association between 
donor D299G and colonization by A. fumigatus, but not inva-
sive disease, in a cohort of T-cell-depleted transplant recipients 
from related donors [145]. Therefore, fungal colonization may not 
predict susceptibility to infection in the presence of D299G, at 
least in this particular transplant setting. The contribution of this 
polymorphism to colonization by A. fumigatus could be explained 
by the fact that an abnormal TLR-4 extracellular domain could 
be hampering its function by disrupting microbial recognition, 
eventually leading to fungal escape from immune surveillance. 
However, TLR-4 polymorphisms have also been shown to display 
a protective effect from hyperinflammatory diseases, including 
atherosclerosis and related conditions [149]. Therefore, the failure 
to recognize the fungus may be compensated by the lack of an 
exuberant inflammatory response to it which may ultimately be 
harmful to the host. In this regard, we have found that a hyper-
inflammatory state, more than the fungus itself, may contribute 
to susceptibility to aspergillosis and other fungal infections [22]. 
Thus, by limiting the inflammatory response to the fungus, the 
D299G polymorphism could contribute to resistance to aspergil-
losis, despite evidence of fungal growth. Interestingly, the D299G 
polymorphism was recently shown to have a unique distribution 
Table 2. Human genetic association studies of polymorphisms in pattern recognition receptors and 
susceptibility to fungal infections.
PRR SNPs SNP source Study definition and sample size† Ref.
TLR-1 R80T R IA (n = 22) versus no IA (n = 105) HSCT patients (p = 0.04) [147]
TLR-1/TLR-6 N248S/S249P R IA (n = 22) versus no IA (n = 105) HSCT patients (p = 0.02) [147]
TLR-4 D299G/T399I Candida BSI (n = 43) versus controls (n = 166; p < 0.05) [137]
TLR-4 D299G/T399I CCPA (n = 40) versus controls (n = 80; p = 0.003) [146]
TLR-4 D299G/T399I D IA (n = 33) versus no IA (n = 303) HSCT patients (discovery study, p = 0.002)
IA (n = 103) versus no IA (n = 263) HSCT patients (validation study, p = 0.02)
[148]
TLR-4 D299G/T399I D Aspergillus-colonized (n = 58) versus noncolonized (n = 51) HSCT 
patients (p = 0.003)
IA (n = 34) versus no IA (n = 24) among precolonized HSCT patients (p = 0.03)
[145]
TLR-9 T-1237C ABPA (n = 22) versus controls (n = 80; p = 0.043) [146]
Dectin-1 Y238X R Candida-colonized (n = 46) versus noncolonized (n = 78) HSCT patients 
(p < 0.001)
[65]
Dectin-1 Y238X D + R IA (n = 39) versus no IA (n = 140) HSCT patients (p = 0.005) [152]
†All genetic association studies described an increased susceptibility to fungal disease, although in [145] the TLR-4 D299G polymorphism was shown to confer 
protection from IA among precolonized patients.
ABPA: Allergic bronchopulmonary aspergillosis; BSI: Bloodstream infection; CCPA: Chronic cavitary pulmonary aspergillosis; D: Donor; HSCT: Hematopoietic stem cell 
transplantation; IA: Invasive aspergillosis; PRR: Pattern recognition receptor; R: Recipient; SNP: Single nucleotide polymorphism; TLR: Toll-like receptor.
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with high prevalence in Africa and low prevalence in Europe, 
with the authors arguing that the benefit from reduced inflam-
mation during malaria in Africa might have been counter-selected 
due to lack of inflammation in response to bacterial infections 
[150].  Although TLR-4 has been representing the cornerstone of 
genetic variability to aspergillosis in the last few years, polymor-
phisms in other TLRs have also been linked with susceptibility 
to fungal infections. In particular, a common promoter poly-
morphism in TLR-9 (T-1237C) has been shown to predispose to 
ABPA, but not severe asthma with fungal sensitization [146] or IA 
following HSCT [145]. It is worth mentioning that we found this 
polymorphism to lead to an increase in TLR-9 gene expression in 
human mononuclear cells that could be further sustained upon 
TLR-9 engagement, presumably resulting in a gain-of-function 
of the receptor [Carvalho A, Almeida AJ, Osório NS  et al.,  Manuscript 
Submitted]. This observation is consistent with a role for TLR-9 in 
response to allergy since TLR-9-deficient mice have been shown 
to be more resistant to induced allergenic stimuli [115]. In addi-
tion, polymorphonuclear cells from these mice had an increased 
capacity to kill conidia and damage Aspergillus hyphae [70], there-
fore arguing for a detrimental role of this TLR-9 polymorphism 
and consequent enhancement of TLR-9 function in allergic 
aspergillosis. Moreover, less well-characterized genetic variants 
in other TLRs, including TLR-1 and -6, have also been reported 
to influence susceptibility to IA after HSCT [147]. Transplant 
recipients harboring either the R80T polymorphism in TLR-1 
or a polymorphism combination in TLR-1 and -6 (N248S and 
S249P, respectively) have an increased risk of IA [147]. The fact 
that polymorphisms in HSCT recipients have been associated 
with aspergillosis suggests that other components in addition to 
hematopoietic cells play an important role in the recognition of 
Aspergillus ligands.
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Figure 2. Human genetic polymorphisms in Toll-like receptors and Dectin-1 are associated with susceptibility to fungal 
infections and result in the functional impairment of the immune response to fungi.
ABPA: Allergic bronchopulmonary aspergillosis; BSI: Bloodstream infection; CCPA: Chronic cavitary pulmonary aspergillosis;  
HSCT: Hematopoietic stem cell transplant; IA: Invasive aspergillosis; TLR: Toll-like receptor.  
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Genetic variants affecting PRRs other than TLRs, in particu-
lar Dectin-1, have also been addressed as potential predictive 
factors for the incidence of fungal infections. A polymorphism 
in human Dectin-1 (Y238X) that generates an early stop codon 
was associated with recurrent mucocutaneous fungal infec-
tions in a Dutch family [65] and with Candida colonization 
after HSCT [39]. This polymorphism, leading to the loss of the 
last ten amino acids of the extracellular domain of Dectin-1, 
results in impaired transport to the cell surface as well as fail-
ure in mediating b-glucan binding [39]. Moreover, monocytes 
and macrophages of affected patients showed impaired cytokine 
responses (IL-6, TNF-a and IL-17), whereas neutrophils exhib-
ited normal phagocytosis and killing of opsonized C. albicans, a 
finding likely contributing to the absence of invasive candidiasis 
in these patients. In addition, the role of the Dectin-1 pathway 
for antifungal host defense has been further supported by a study 
identifying a family with mutations in CARD9, displaying an 
almost complete defect in the generation of Th17 responses, 
rendering them more susceptible to mucocutaneous Candida 
infections [151].
We have also recently found that the functional Y238X poly-
morphism in Dectin-1 increased susceptibility to IA among 
HSCT patients [152]. The increased susceptibility to aspergillosis 
underlined by the Y238X polymorphism was found to rely on 
both donor and recipient genetic make-ups, with the effect being 
more prominent in conditions in which both donors and recipi-
ents simultaneously harbored the variant. Although Dectin-1 
has been regarded as one major innate receptor leading to Th17 
activation in response to Aspergillus [60], and the Y238X poly-
morphism was associated with impaired IL-17 production in 
response to C. albicans or b-glucan [153], we found that IFN-g 
and IL-10, in addition to IL-17A, production by human mono-
nuclear cells harboring the Y238X polymorphism were defective 
upon Aspergillus challenge [152]. Thus, these findings point to a 
previously unsuspected role for Dectin-1 in antifungal immu-
nity, that is, the ability to modulate immunity and tolerance via 
IFN-g/IL-10 production, both cytokines reflecting the activa-
tion of protective Th1/Treg antifungal responses in mice [67] 
and humans [37]. The high risk of infection seen in conditions 
of recipient Dectin-1 deficiency also points to a crucial role for 
Dectin-1 expressed on nonhematopoietic cells in the induction 
of immune protection to the fungus. Incidentally, Dectin-1 has 
been shown to have an inducible expression in ECs and to play 
a critical role in mounting the innate immune responses in non-
phagocytic cells [66]. Overall, these findings highlight the mul-
tiple roles Dectin-1 may have in host resistance to Aspergillus that 
is likely achieved through distinct, yet complementary, mecha-
nisms of immune resistance and tolerance that are dependent on 
hematopoietic/nonhematopoietic compartmentalization.
Expert commentary & five-year view
A finely orchestrated balance between activating and inhibitory 
signals is fundamental for the ability of the immune system to 
effectively attack and eliminate pathogenic fungi and/or coex-
ist with commensals without reacting against self-antigens. 
Derangements of this balance may underlie the pathogenesis of 
chronic infections and autoimmune inflammatory diseases. The 
new discoveries in the field of fungal immunology have offered 
new grounds for a better comprehension of cells and immune 
pathways that are amenable to manipulation in patients with or 
at risk of fungal infections. The very active research of the past 
few years has greatly improved our understanding of how the 
fungal pathogens are recognized as nonself by the host defense, 
allowing us to propose integrated models of innate recognition 
of these important human pathogens [54].
The use of TLR agonists has recently been explored and sev-
eral clinical trials are currently underway in an attempt to target 
various TLRs for the development of vaccine adjuvants, anti-
infectious agents and anticancer agents [154]. In this sense, a very 
important task of future studies will be to identify the adjuvant 
activity of specific PRR ligands in the context of fungal vac-
cination. Both combinations of various candidate vaccines with 
known and possibly novel TLR/CLR adjuvants are interesting 
options for the development of antifungal vaccines. Additional 
areas of investigation include a deepened understanding of TLR 
regulation, considering their role as ‘double-edged swords’ in 
promoting protective versus detrimental effects on antifungal 
immunity.
Finally, although the dissection of complex genetic traits 
modulating susceptibility to fungal infections is complex, the 
contribution of host genetics may hold the key to elucidate new 
risk factors for these severe, often fatal diseases. In this sense, 
new conceptual advances on the knowledge of host immunity 
also need to be accommodated from an immunogenetic point of 
view. Understanding host–pathogen interactions at the innate 
immune interface, together with the cellular and molecular bases 
affected by host genetic variables, will prove a very powerful 
research tool, allowing the identification of potential therapeutic 
targets and the design of prophylactic strategies exerting control 
over the outcome of immune pathways. The genetic screening of 
at-risk patients may ultimately be used to individualize treatments 
through the formulation of new targeted and patient-tailored 
antifungal therapeutics, likely improving the management and 
outcome of fungal infections.
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